3o56: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:3o56.jpg|left|200px]] | |||
The | <!-- | ||
The line below this paragraph, containing "STRUCTURE_3o56", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
--> | |||
{{STRUCTURE_3o56| PDB=3o56 | SCENE= }} | |||
===Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor=== | |||
<!-- | |||
The line below this paragraph, {{ABSTRACT_PUBMED_20732811}}, adds the Publication Abstract to the page | |||
(as it appears on PubMed at http://www.pubmed.gov), where 20732811 is the PubMed ID number. | |||
--> | |||
{{ABSTRACT_PUBMED_20732811}} | |||
==About this Structure== | |||
[[3o56]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3O56 OCA]. | |||
==Reference== | |||
<ref group="xtra">PMID:020732811</ref><references group="xtra"/> | |||
[[Category: 3',5'-cyclic-nucleotide phosphodiesterase]] | |||
[[Category: Homo sapiens]] | |||
[[Category: Neu, M.]] | |||
[[Category: Somers, D O.]] | |||
[[Category: Camp binding]] | |||
[[Category: Hydrolase]] | |||
[[Category: Hydrolase-hydrolase inhibitor complex]] | |||
[[Category: Pde]] | |||
[[Category: Phosphodiesterase]] |
Revision as of 11:46, 3 August 2011
Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitorCatalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor
Template:ABSTRACT PUBMED 20732811
About this StructureAbout this Structure
3o56 is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
- ↑ Mitchell CJ, Ballantine SP, Coe DM, Cook CM, Delves CJ, Dowle MD, Edlin CD, Hamblin JN, Holman S, Johnson MR, Jones PS, Keeling SE, Kranz M, Lindvall M, Lucas FS, Neu M, Solanke YE, Somers DO, Trivedi NA, Wiseman JO. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5803-6. Epub 2010 Aug 5. PMID:20732811 doi:10.1016/j.bmcl.2010.07.136